Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)

NCT00298896 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.

NCT NCT00298896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)
Lead sponsor
Sunesis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
June 30, 2008
Enrollment
55 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell, small cell lung cancer